EC Number   |
Application |
Reference |
|---|
   2.1.1.228 | drug development |
bacterial tRNA (guanine37-N1)-methyltransferase (TrmD) from Pseudomonas aeruginosa is a good target for development of antibacterial compounds |
-, 756152 |
| 2.1.1.228 | drug development |
bacterial tRNA modification synthesis pathways are critical to cell survival under stress and thus represent ideal mechanism-based targets for antibiotic development. tRNA-(N1G37) methyltransferase (TrmD) is a target, which is conserved and essential in many bacterial pathogens |
-, 755697 |
| 2.1.1.228 | drug development |
the enzyme is a target for antibiotic development |
-, 758329 |
| 2.1.1.228 | drug development |
the enzyme is an attractive target for development of antibacterial drugs against Mycobacterium abscessus, which possesses both intrinsic and acquired resistance to available antibiotics and is therefore currently difficult or sometimes impossible to treat |
757408 |
| 2.1.1.228 | drug development |
TrmD has potential as a drug target |
735927 |
| 2.1.1.228 | drug development |
TrmD is a leading antimicrobial drug target, due to its essentiality for bacterial growth, its broad conservation across bacterial species, and its deep-rooted distinction from the human and archaeal counterpart Trm5, which has the dinucleotide fold |
757790 |
| 2.1.1.228 | drug development |
TrmD is ranked as a high-priority antimicrobial target |
-, 756631 |
| 2.1.1.228 | medicine |
the sequence and structural distinction of bacterial TrmD from the eukaryotic Trm5 suggests that strategies can be developed to specifically inhibit TrmD without a deleterious effect on humans |
662622 |
